Compass Pathways Plc ADR
Open
11.9 -1.57
Overzicht
Wijziging aandelenprijs
24u
Min
12.03
Max
12.26
Inkomsten | 185M 91M |
|---|---|
EPS | -0.3 |
Werknemers | 156 |
EBITDA | 139M 93M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +94.54% upside |
Volgende Winsten | 30 jul 2026 |
|---|
Marktkapitalisatie | 211M 1.5B |
|---|---|
Vorige openingsprijs | 13.47 |
Vorige sluitingsprijs | 11.9 |
Compass Pathways Plc ADR Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
